Atrium Doses First Patient in Phase 1/2 PRKAG2 Trial

Atrium Therapeutics announced the dosing of the first patient in its Phase 1/2 Corventis trial for the potential treatment of PRKAG2 syndrome, targeting the genetic root cause of this rare genetic cardiomyopathy.